Small molecule tyrosine kinase inhibitors have great potential for the treatment of HCC through targeting several growth factors and their associated signaling pathways (e.g. EGF/EGFR, VEGF/VEGFR, IGF/IGFR, PDGF, FGF, RAS/RAF/ERK/MAPK, PI3K/AKT/mTOR, Wnt/beta-catenin) [104,105]. Here, EGFR is linked to hepatocellular carcinoma.